Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 266724

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Drug Testing

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 266724

License Grant
Licensor, a charitable organization,  grants to Licensee an exclusive license to Licensors right, title and interest under Patent Rights and Biological Materials and a non-exclusive license under Licensors right, title and interest in Technical
Information, with the right to grant sublicenses, to make, have made, use, offer to sell, sell and import Licensed Products and Developed Products, to provide Licensed Services and to practice Licensed Processes in the Territory in the Field of Use.

Licensor grants to Licensee an exclusive three (3) month option, from the date of disclosure in writing by Licensor to Licensee, to obtain an exclusive license, on terms to be negotiated in good faith based on industry standards, to Licensors right, title and interest in future inventions from the laboratory of Dr. Ronald DePinho or Dr. Lynda Chin, the practice of which Licensor believes, in the exercise of its sole reasonable judgment, would infringe Patent Rights.

Licensor has informed Licensee and Licensee acknowledges that certain items of Biological Materials are covered by U.S. Patents 4,736,866, 5,087,571 and 5,925,803, and corresponding foreign patents, and any patents granted on any divisional and continuation applications thereof, and cannot be transferred to Licensee from Licensor until Licensee enters into a license with the designated Third Party.

License Property
Invention means inducible mouse models of cancer, including without limitation, RAS and second site suppression models, telomere-based system for cancer gene discovery and mouse models of cancer based on tissue stem cell transgenesis.

The patents include Direct Functional Categorization of Gene Candidates by One-Hit Mammalian Second Site Suppressor {MaSS) Screen;  Inducible Cancer Model to Study the Molecular basis of host-tumor cell interactions in vivo;  Generation of mouse models of human cancer using tissue specific stem cells (Stem Transgenesis); and, Telornere-based mouse and human cell-based model systems for the discovery of cancer genes using established genomic technologies.

The Licensor materials are clnk4a+/-H12 cells.

“Invention” means inducible mouse models of cancer, including without limitation, RAS and second site suppression models, telomere-based system for cancer gene discovery and mouse models of cancer based on tissue stem cell transgenesis.

Field of Use
The Field of Use means all fields of use.

Patents cover germ line transgenic mouse models of cancer, and a method of using spontaneous inducible mouse tumor models to screen for, and identify, novel targets for new cancer drugs

IPSCIO Record ID: 368517

License Grant
The Parties previously entered an agreement to discover targets suitable for the development of small molecule oncology therapeutic and/or prophylactic agents which target essential tumor maintenance genes.

For Therapeutic Use, Licensor grants an exclusive license in the Territory under the Licensor Patent Rights and Know-How, with a right to sublicense for any and all Therapeutic Uses, to develop, make, have made, use, offer to sell, sell and/or import Collaboration Compounds and/or Products Directed at such Non-MAP  Collaboration Target for Therapeutic Use.

For Diagnostic Use, Licensor grants to a non-exclusive license in the Territory under the Licensor Patent Rights and Know-How, with a right to sublicense for any and all Diagnostic Use, to develop, make, have made, use, offer to sell, sell and/or import Collaboration Compounds and/or Products Directed at such Non-MAP Collaboration Target for Diagnostic Use.

For Biologicals, Licensor grants a non-exclusive license in the Territory under the Licensor Patent Rights and Licensor Know-How, with a right to sublicense to Licensees Affiliates to develop, make, have made and use Biologicals Directed to a NonMAP Collaboration Target or Discovery Target for the sole purpose of the research and/or development of a Product for Therapeutic Use and/or Diagnostic Use.

For MAP Collaboration Targets,  Licensor grants a non-exclusive license under the Licensor Patent Rights and Know-How that arise from the activities under the MAP Target Research Plan to develop, make, have made, use, offer to sell, sell and/or import inhibitors or modulators directed to such MAP Collaboration Target for Therapeutic Use and Diagnostic Use.

For Option for Non-MAP Collaboration Targets, Licensor grants an exclusive Option to obtain an exclusive license, and a non-exclusive license, for up to seven Non-MAP Nominated Targets at any one time.

License Property
Licensor has developed Know-How and has rights to related Patent Rights.

Licensor Genetic Screen Data means all data with respect to Potential Collaboration Targets generated by A YEO in conducting the MaSS Screen under the Research Program using the Collaboration Models.

Pilot Experiments mean the portion of the Research Program which involves the use of Licensors proprietary INK4A-/-/kRAS Spontaneous Inducible Melanoma Model to explore the potential use of Licensors proprietary model systems for responder identification.

Target means a nucleotide sequence, including all expressed variants of such nucleotide sequence.

Target Package shall mean the package of info1mation relating to a Non-MAP Nominated Target.

Target packages include, but are not limited to
—  Recurrence Information regarding frequency of integration in MaSS Screen or cDNA complementation screen in Collaboration Models, along with map of integration site.
—  Homology and Human Expression Identity and degree of homology between murine gene and closest human homolog. Available data regarding expression of target in human tissues and tumors.
—  Cellular Location Outcome of algorithm(s) to predict cellular location (intracellular v. extracellular) and/or reference(s) to experimental evidence demonstrating actual cellular location.

Licensor's Human Response Prediction platform is based on Licensor's proprietary, genetically-defined mouse models of human cancer. Each of these models is engineered to contain signature genetic mutations that are present in human disease. Beyond these cancer-initiating engineered mutations, the resultant tumors acquire common and distinct spontaneous mutations during tumor progression, providing additional natural genetic variation more akin to the range of genetic heterogeneity encountered across different primary human tumors. The tumor-to-tumor genetic variation in the system provides the opportunity to identify genetic correlations between responding and non- responding tumor populations, and to apply such genetic profiles in clinical development.  Consequently, compared with traditional xenograft models that have proven to be non-predictive of efficacy, often leading to expensive and time consuming hit or miss outcomes in clinical trials, Licensor's cancer models are improved predictors of human response.

Field of Use
The collaboration is focused on identifying genetic profiles that correlate with drug response to more effectively guide the clinical and market development of Licensee's cancer compounds.

The Field means the use of Non-MAP Collaboration Targets, MAP Collaboration Targets, Discovery Targets, Collaboration Compounds and/or Products for any and all Therapeutic Uses and/or Diagnostic Uses.

IPSCIO Record ID: 300744

License Grant
This agreement is to identify Prognostic Signatures capable of predicting responsiveness of an organism to therapeutic compounds upon the terms and conditions.

For Therapeutic Use, upon exercise of the Option for a specified Non-MAP Collaboration Target,  Licensor grants  an exclusive license in the Territory under the Licensor Patent Rights and Licensor Know-How, with a right to sublicense for any and all Therapeutic Uses, to develop, make, have made, use, offer to sell, sell and/or import Collaboration Compounds and/or Products Directed at such Non-MAP Collaboration Target for Therapeutic Use.

For Diagnostic Use, upon exercise of the Option for a specified Non-MAP Collaboration Target Licensor grants a non-exclusive license in the Territory under the Licensor Patent Rights and Licensor Know-How, with a right to sublicense for any and all Diagnostic Use, to develop, make, have made, use, offer to sell, sell and/or import Collaboration Compounds and/or Products Directed at such Non-MAP Collaboration Target for Diagnostic Use.

For Biologicals, upon exercise of the Option for a specified Non-MAP Collaboration Target that is not an Additional Biological Target,  Licensor grants a non-exclusive license in the Territory under the Licensor Patent Rights and Licensor Know-How, with a right to sublicense, to develop, make, have made and use Biologicals Directed to a NonMAP Collaboration Target or Discovery Target for the sole purpose of the research and/or development of a Product for Therapeutic Use and/or Diagnostic Use.

For MAP Collaboration Targets, upon Licensees payment of the MAP Technology Access Fee for a specified MAP Collaboration Target Licensor grants a non-exclusive license under the Licensor Patent Rights and Licensor Know-How that arise from the activities under the MAP Target Research Plan to develop, make, have made, use, ·
offer to sell, sell and/or import inhibitors or modulators directed to such MAP Collaboration Target for Therapeutic Use and Diagnostic Use.

For the Option for Non-MAP Collaboration Targets, Licensor grants an exclusive Option to obtain an exclusive license, and a non-exclusive license for up to seven Non-MAP Nominated Targets at any one time.

License Property
Collaboration Model means
—   INK4A-/-/kRAS Spontaneous Inducible Breast Cancer Model
—   INK4A-/-/HER2 Spontaneous Inducible Breast Cancer Model
—   INK4A-/-/kRAS Spontaneous Inducible Lung Cancer Model.

Product means any preparation in final form, either for sale by prescription, over-the-counter or any other method or for administration to human patients in Clinical Trials, for any and all uses in the Field, which preparation contains a Collaboration Compound, or in the case of a Product for Diagnostic Use, utilizes the relevant Discovery Target and/or Collaboration Compound for Diagnostic Use.

Human Response Platform is a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients.

Human Response Prediction platform is based on AVEO's proprietary, genetically-defined mouse models of human cancer. Each of these models is engineered to contain signature genetic mutations that are present in human disease. Beyond these cancer-initiating engineered mutations, the resultant tumors acquire common and distinct spontaneous mutations during tumor progression, providing additional natural genetic variation more akin to the range of genetic heterogeneity encountered across different primary human tumors. The tumor-to-tumor genetic variation in the system provides the opportunity to identify genetic correlations between responding and non- responding tumor populations, and to apply such genetic profiles in clinical development.

Field of Use
Human Response Platform provides an unique insights into cancer biology and mechanisms of drug response and resistance, and represents a significant improvement over traditional approaches.  The parties will use the Human Response Prediction platform to identify patient populations likely to be responsive to a number of investigational cancer drugs currently being developed.  The collaboration is focused on identifying genetic profiles that correlate with drug response to more effectively guide the clinical and market development of Licensee's cancer compounds.

Field means the use of Non-MAP Collaboration Targets, MAP Collaboration Targets, Discovery Targets, Collaboration Compounds and/or Products for any and all Therapeutic Uses and/or Diagnostic Uses.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.